Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CNTA |
---|---|---|
09:38 ET | 699 | 8.75 |
09:39 ET | 1780 | 8.8 |
09:41 ET | 800 | 8.8 |
09:48 ET | 100 | 8.78 |
09:52 ET | 100 | 8.77 |
09:54 ET | 2200 | 8.8102 |
09:56 ET | 1441 | 8.92 |
10:06 ET | 813 | 8.92 |
10:12 ET | 400 | 8.875 |
10:17 ET | 388 | 8.88 |
10:19 ET | 10100 | 8.88 |
10:21 ET | 2276 | 8.89 |
10:32 ET | 902 | 8.93 |
10:37 ET | 200 | 8.98 |
10:39 ET | 400 | 8.99 |
10:42 ET | 200 | 8.98 |
10:44 ET | 25600 | 9 |
10:46 ET | 565 | 9.04 |
10:50 ET | 5615 | 8.99 |
10:51 ET | 600 | 8.97 |
10:53 ET | 4578 | 8.97 |
10:55 ET | 858 | 8.99 |
10:57 ET | 200 | 9 |
11:02 ET | 100 | 9 |
11:08 ET | 100 | 8.99 |
11:13 ET | 1000 | 9 |
11:15 ET | 2005 | 8.99 |
11:18 ET | 1606 | 9 |
11:20 ET | 4496 | 9 |
11:22 ET | 6985 | 8.97 |
11:24 ET | 400 | 8.965 |
11:33 ET | 100 | 8.95 |
11:40 ET | 600 | 8.97 |
11:42 ET | 300 | 8.98 |
11:45 ET | 100 | 9 |
11:47 ET | 100 | 9 |
11:49 ET | 100 | 8.99 |
11:51 ET | 200 | 8.975 |
11:56 ET | 200 | 8.98 |
12:00 ET | 200 | 8.97 |
12:02 ET | 2802 | 8.91 |
12:03 ET | 2334 | 8.94 |
12:09 ET | 7778 | 8.94 |
12:12 ET | 7719 | 8.92 |
12:23 ET | 300 | 8.9 |
12:25 ET | 809 | 8.89 |
12:27 ET | 100 | 8.9 |
12:32 ET | 1188 | 8.93 |
12:34 ET | 214 | 8.92 |
12:39 ET | 200 | 8.915 |
12:41 ET | 220 | 8.9025 |
12:43 ET | 100 | 8.9 |
12:45 ET | 300 | 8.92 |
12:52 ET | 400 | 8.91 |
12:56 ET | 200 | 8.9 |
12:57 ET | 100 | 8.9 |
01:01 ET | 5487 | 8.9 |
01:06 ET | 300 | 8.895 |
01:08 ET | 800 | 8.9 |
01:10 ET | 100 | 8.9 |
01:14 ET | 108 | 8.9 |
01:15 ET | 400 | 8.91 |
01:17 ET | 200 | 8.91 |
01:19 ET | 200 | 8.91 |
01:21 ET | 813 | 8.9 |
01:24 ET | 200 | 8.89 |
01:26 ET | 619 | 8.89 |
01:28 ET | 2367 | 8.9 |
01:32 ET | 100 | 8.905 |
01:33 ET | 2331 | 8.88 |
01:35 ET | 2634 | 8.9 |
01:37 ET | 200 | 8.9 |
01:39 ET | 400 | 8.89 |
01:44 ET | 100 | 8.905 |
01:46 ET | 200 | 8.9 |
01:48 ET | 307 | 8.9 |
01:50 ET | 100 | 8.9 |
01:51 ET | 800 | 8.9 |
01:53 ET | 100 | 8.9 |
01:55 ET | 400 | 8.9 |
01:57 ET | 1358 | 8.9 |
02:00 ET | 100 | 8.9 |
02:02 ET | 300 | 8.9 |
02:06 ET | 400 | 8.9 |
02:08 ET | 200 | 8.9 |
02:09 ET | 100 | 8.9 |
02:11 ET | 500 | 8.9 |
02:13 ET | 2941 | 8.92 |
02:15 ET | 1206 | 8.92 |
02:18 ET | 300 | 8.9 |
02:20 ET | 700 | 8.9 |
02:24 ET | 500 | 8.91 |
02:29 ET | 400 | 8.9 |
02:33 ET | 1365 | 8.91 |
02:36 ET | 200 | 8.91 |
02:38 ET | 3158 | 8.91 |
02:40 ET | 300 | 8.905 |
02:42 ET | 100 | 8.905 |
02:44 ET | 400 | 8.9 |
02:45 ET | 300 | 8.9 |
02:47 ET | 100 | 8.905 |
02:49 ET | 1000 | 8.91 |
02:51 ET | 227 | 8.91 |
02:54 ET | 100 | 8.91 |
02:56 ET | 313 | 8.91 |
02:58 ET | 4088 | 8.91 |
03:00 ET | 500 | 8.92 |
03:02 ET | 200 | 8.92 |
03:05 ET | 200 | 8.92 |
03:07 ET | 200 | 8.925 |
03:09 ET | 1000 | 8.9 |
03:12 ET | 1000 | 8.87 |
03:14 ET | 704 | 8.89 |
03:16 ET | 2551 | 8.89 |
03:18 ET | 102 | 8.89 |
03:21 ET | 1139 | 8.88 |
03:23 ET | 362 | 8.89 |
03:25 ET | 2362 | 8.89 |
03:30 ET | 100 | 8.88 |
03:32 ET | 100 | 8.88 |
03:34 ET | 3999 | 8.805 |
03:36 ET | 700 | 8.805 |
03:39 ET | 460 | 8.7938 |
03:41 ET | 700 | 8.805 |
03:43 ET | 571 | 8.8 |
03:45 ET | 808 | 8.79 |
03:48 ET | 600 | 8.78 |
03:50 ET | 1999 | 8.79 |
03:52 ET | 418 | 8.77 |
03:54 ET | 425 | 8.79 |
03:56 ET | 1039 | 8.75 |
03:57 ET | 4142 | 8.735 |
03:59 ET | 9606 | 8.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Centessa Pharmaceuticals PLC | 991.4M | -6.2x | --- |
Pharvaris NV | 907.3M | -6.6x | --- |
Enliven Therapeutics Inc | 1.0B | -11.3x | --- |
Cullinan Therapeutics Inc | 940.0M | -5.2x | --- |
Rapport Therapeutics Inc | 914.8M | -17.2x | --- |
Autolus Therapeutics PLC | 899.2M | -2.8x | --- |
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $991.4M |
---|---|
Revenue (TTM) | $6.9M |
Shares Outstanding | 113.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.42 |
Book Value | $2.39 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | 144.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,312.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.